VectorY develops vectorized antibodies using AAV capsids to create therapeutics for neurodegenerative diseases such as ALS, Huntington’s, and Parkinson’s disease. The company aims to provide disease-modifying treatments that enhance the quality of life for patients suffering from these conditions.
Funding
$174.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ELFCFounders
Product
Problem
Neurodegenerative diseases like ALS, Huntington’s, and Parkinson’s disease lack effective disease-modifying treatments, leading to a decline in quality of life for affected individuals. Current therapeutic approaches often fail to adequately address the underlying causes and progression of these conditions.
Solution
VectorY develops vectorized antibodies delivered via adeno-associated virus (AAV) capsids to target the intracellular environment and modify the course of neurodegenerative diseases. Their platform combines intracellular antibodies, AAV capsid technology, and manufacturing expertise to create potentially disease-modifying treatments. By delivering antibodies directly to the affected cells, VectorY aims to provide more effective and targeted therapies for conditions like ALS, Huntington’s, and Parkinson’s disease.
Target Audience
The primary target audience includes patients suffering from neurodegenerative diseases such as ALS, Huntington’s, and Parkinson’s disease, as well as the healthcare providers who treat them.
Features
- Vectorized antibody delivery using AAV capsids for targeted intracellular access.
- Proprietary platform combining intracellular antibodies, AAV capsid engineering, and manufacturing processes.
- Pipeline of vectorized antibody treatments for ALS, Huntington’s, and Parkinson’s disease.